Evidence map›Paper›PMID 40223110›Full record

ArticleHead & face medicine2025

Predictors of disease alleviation with mandibular advancement devices in obstructive sleep apnea: a retrospective cohort study.

Eva Paddenberg-Schubert, Benedikt Holmer, Sebastian Krohn, Helmut Hösl, Peter Proff, Christian Kirschneck, Michael Arzt

Abstract read
In one paragraph

Article in Head & face medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Redefining Obstructive Sleep Apnea: Treatment in the Modern Era.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  3. Mandibular advancement devices in obstructive sleep apnea: diagnostic predictors for treatment response and clinical implications : A retrospective pilot cohort study.Journal of orofacial orthopedics = Fortschritte der Kieferorthopadie : Organ/official journal Deutsche Gesellschaft fur Kieferorthopadie · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eva Paddenberg-SchubertDepartment of Orthodontics, University Hospital Regensburg, 93053, Regensburg, Germany. eva.paddenberg@klinik.uni-regensburg.de.
Benedikt HolmerDepartment of Orthodontics, University Hospital Regensburg, 93053, Regensburg, Germany.
Sebastian KrohnDepartment of Orthodontics, University Hospital Regensburg, 93053, Regensburg, Germany.
Helmut HöslDepartment of Orthodontics, University Hospital Regensburg, 93053, Regensburg, Germany.
Peter ProffDepartment of Orthodontics, University Hospital Regensburg, 93053, Regensburg, Germany.
Christian KirschneckDepartment of Orthodontics, University of Bonn, 53111, Bonn, Germany.
Michael ArztCentre of Sleep Medicine, Department of Internal Medicine II, University Hospital Regensburg, 93053, Regensburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundObstructive sleep apnea (OSA) can be treated with mandibular advancement devices (MAD), preventing collapse of the upper airway and decreasing apnea-hypopnea index (AHI)/ h. Disease alleviation is expected to vary depending on specific predictors including OSA-severity and cephalometric parameters. This retrospective cohort study aimed to identify predictors of disease alleviation with MAD in adult patients with mild to moderate and severe OSA. Secondary outcomes included assessing the necessity of lateral cephalograms and the therapeutic success in severe OSA-cases.

methodsOSA-patients, treated with MAD at the orthodontic department of the University Hospital Regensburg, Germany, were allocated to mild to moderate (AHI ≤ 30/ h) and severe OSA groups (AHI > 30/ h). BMI, poly(somno)graphic, demographic and cephalometric variables were evaluated before (T0) and after 3 to 6 months of MAD-treatment (T1). Applying linear regression analyses, predictors were identified, following an assessment of their effect on disease alleviation by independent two-tailed t-tests for continuous, and absolute and relative frequencies for categorical variables. Then, the need for cephalometric analysis and the disease alleviation in severe OSA-patients were evaluated.

resultsSixty-six predominantly male patients (mean age 55 ± 11 years; male:female = 52:14) were stratified to mild to moderate (n = 45) and severe (n = 21) OSA-groups. Regression analysis revealed baseline-AHI as a significant and relevant predictor, whereas few cephalometric parameters proved significance with small effect sizes (absolute AHI/ h-reduction, univariate model: -0.64 (95% CI: -0.75; -0.53), p < 0.001, R² = 0.666). Compared to mild to moderate OSA-cases, severe OSA-patients had a significantly higher AHI (19.1 ± 11.7 vs. 6.0 ± 4.0, p < 0.001) at T1, but also a higher disease alleviation according to absolute AHI-reduction (-26.1 ± 16.0 vs. -9.6 ± 6.4, p < 0.001), indicating comparable treatment success in all OSA-degrees.

conclusionsDisease alleviation with MAD in adult OSA-patients can be predicted with specific poly(somno)graphic parameters (especially baseline-AHI), whereas cephalometric variables appeared inappropriate. Still, lateral cephalograms are helpful in the diagnostics and follow-up of MAD-treatment, e.g. for evaluating side effects. Providing good patient selection, therapeutic success can be achieved in both severe and mild to moderate OSA.

Indexed as

Mandibular AdvancementSleep Apnea, ObstructiveAdultAgedCephalometryFemaleGermanyHumansMaleMiddle AgedPolysomnographyRetrospective StudiesSeverity of Illness IndexTreatment OutcomeApnea-hypopnea indexLateral cephalogramSleep disorderTreatment success

Identifiers

PMID40223110
PMCPMC11995498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.